Idenix reports progress on two hepatitis C candidates
10:09 EDT 21 Jun 2012 | SCRIP
Cambridge, Massachusetts-based Idenix Pharmaceuticals has reported positive data from both an interim analysis of a Phase II study of its drug candidate for hepatitis C virus (HCV), IDX184, and a three-day proof-of-concept trial for another HCV....
Original Article: Idenix reports progress on two hepatitis C candidates
More From BioPortfolio on "Idenix reports progress on two hepatitis C candidates"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
